Reading TELA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TELA free→Reading TELA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TELA free→NASDAQHealth CareMedical DevicesSnapshot 2026-06-12
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak, and the company was unprofitable over the past year, so its earnings quality can't be assessed. Management's recent track record has been fairly steady, and it has a capital-friendly approach. Risk is high, and the sector backdrop is a headwind, with TELA trading below typical compared to its sector peers. Peer multiples imply a price about 81% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk, as it trades below peer multiples, but recent financials are weak. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 1 valuation methods, at three horizons. Current price $0.86. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $0.86 TELA trades at 1× p/s, below its 3× p/s peer median. Our $5.29 fair value sits above the price; low confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 84% below a flat-multiple fair value, below our forecast of about 22%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 0.75x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates.
1 material management or governance event in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.18 → $-0.18 (-1.1% / 30d). 0 raised, 1 cut, 5 covering analysts.
0 upgrades, 0 downgrades / 30d. 80% of analysts rate Buy.
0 positive, 0 negative / 30d.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$502.
How much price usually moves either way.
On a bad day, this stock has moved -$884.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $7,382.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-12
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for TELA yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 9, 2026, at the 2026 Annual Meeting of Stockholders (the “ Annual Meeting ”) of TELA Bio, Inc. (the “ Company ”), the Company’s stockholders approved the amendment (the “ Plan Amendment ”) to the Company’s Amended and Restated 2019 Equity Incentive Plan, as amended (the “ A&R 2019 Plan ”), to, among other things, increase the authorized sha…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
TELA Tela Bio Inc | Below typical Show detailsSector percentile: 25 of 100 | inexpensive | high |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 93 of 100 | inexpensive | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Typical Show detailsSector percentile: 67 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
Not investment advice. As of 2026-06-12.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-12.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Management aims to achieve at least 8% revenue growth over the full year 2025.
Stated in 2 of last 2 quarters. Revenue for 2025 was $80.2 million. Management has reiterated the goal of achieving at least 8% growth in 2026, but Q1 2026 revenue was $19.1 million, indicating limited progress towards the annual target.
“Reiterated full year 2026 revenue guidance of at least 8% growth over full year 2025.”
“Confident in the team’s ability to deliver at least 8% revenue growth in 2026.”
Management expects second quarter 2026 revenue to be approximately $20 million.
Newly stated in 2026-Q1. Q1 2026 revenue was $19.1 million. Management expects Q2 2026 revenue to reach $20 million, indicating a slight increase from the previous quarter. The trajectory is on track if the target is met.
“Second quarter 2026 revenue is expected to be approximately $20.0 million.”